Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Forbion is a global venture capital firm founded in the 1990s, originally as ABN AMRO Capital Life Sciences, and rebranded in 2006. The firm is headquartered in the Netherlands, Germany, and the United States, managing over €5 billion across multiple fund strategies. Their team consists of over 50 investment professionals focused on all stages of (bio-)pharmaceutical drug development.
Forbion invests in innovative biotech companies addressing unmet medical needs and sustainable solutions. Their Human Health strategy supports biopharmaceutical companies through seed funding and expansion, focusing on areas like oncology, immunology, and rare genetic disorders. The BioEconomy strategy targets sustainable innovations in food, agriculture, materials, and environmental technologies.
Forbion's portfolio includes notable companies such as Azafaros, which focuses on treatments for severe rare genetic diseases; VectorY, an integrated gene therapy company for central nervous system diseases; and Genomines, pioneering plant-based metal extraction technologies.
Email info@forbion.com with your deck to pitch them directly.
Forbion often leads investment rounds, particularly in seed and Series A stages, to help build and expand promising biotech companies.
Forbion actively participates in follow-on investments to support portfolio companies as they grow and reach new milestones.
Forbion manages over €5 billion across various fund strategies, allowing for significant investments across multiple stages.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.